tiprankstipranks
Advertisement
Advertisement

KYMR Stock Latest News

Kymera Therapeutics price target raised to $125 from $110 at BofA
The FlyKymera Therapeutics price target raised to $125 from $110 at BofA
11d ago
KYMR
Kymera Therapeutics: Accelerated KT-621 Development, $6B Peak Sales Potential, and Raised Price Target to $125 Support Buy Rating
PremiumRatings
Kymera Therapeutics: Accelerated KT-621 Development, $6B Peak Sales Potential, and Raised Price Target to $125 Support Buy Rating
12d ago
KYMR
Kymera Therapeutics price target raised to $155 from $117 at B. Riley
PremiumThe Fly
Kymera Therapeutics price target raised to $155 from $117 at B. Riley
12d ago
KYMR
Kymera Therapeutics price target raised to $136 from $116 at Truist
PremiumThe Fly
Kymera Therapeutics price target raised to $136 from $116 at Truist
12d ago
KYMR
Kymera Therapeutics price target raised to $129 from $106 at Canaccord
PremiumThe Fly
Kymera Therapeutics price target raised to $129 from $106 at Canaccord
15d ago
KYMR
Kymera: Accelerated Atopic Dermatitis Timeline and KT-621 Potential Drive Jeet Mukherjee’s Buy Rating
PremiumRatingsKymera: Accelerated Atopic Dermatitis Timeline and KT-621 Potential Drive Jeet Mukherjee’s Buy Rating
15d ago
KYMR
Midday Fly By: Micron reports blowout Q3, Apple boosts MacBook prices
Premium
The Fly
Midday Fly By: Micron reports blowout Q3, Apple boosts MacBook prices
16d ago
BB
GS
Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment
Premium
Market News
Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment
16d ago
KYMR
Kymera Therapeutics rises 18.6%
PremiumThe Fly
Kymera Therapeutics rises 18.6%
16d ago
KYMR
Kymera Completes Enrollment in KT-621 Atopic Dermatitis Trial
PremiumCompany Announcements
Kymera Completes Enrollment in KT-621 Atopic Dermatitis Trial
16d ago
8K
KYMR
Kymera Therapeutics completes enrollment in BROADEN2 trial
PremiumThe Fly
Kymera Therapeutics completes enrollment in BROADEN2 trial
16d ago
KYMR
Kymera Shareholders Reelect Directors, Affirm Executive Pay, Auditor
PremiumCompany Announcements
Kymera Shareholders Reelect Directors, Affirm Executive Pay, Auditor
17d ago
8K
KYMR
Kymera Therapeutics appoints Felix Baker as chairman
PremiumThe FlyKymera Therapeutics appoints Felix Baker as chairman
17d ago
KYMR
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
Premium
The Fly
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
19d ago
ABBV
APGE
Kymera Therapeutics participates in a conference call with JPMorgan
Premium
The Fly
Kymera Therapeutics participates in a conference call with JPMorgan
24d ago
KYMR
Kymera Therapeutics: Buy Rating Reiterated as Analyst Maintains $110 Price Target on Emerging Protein Degrader Pipeline
PremiumRatings
Kymera Therapeutics: Buy Rating Reiterated as Analyst Maintains $110 Price Target on Emerging Protein Degrader Pipeline
1M ago
KYMR
Kymera Therapeutics COO Resigns, Transition Plan Implemented
PremiumCompany Announcements
Kymera Therapeutics COO Resigns, Transition Plan Implemented
1M ago
8K
KYMR
Kymera Therapeutics presents preclinical lupus data for KT-579
PremiumThe Fly
Kymera Therapeutics presents preclinical lupus data for KT-579
1M ago
KYMR
Sanofi and Kymera Advance SAR447971 Into First-in-Human Trial, Setting Up New Optionality in Inflammatory Skin Disease
PremiumCompany Announcements
Sanofi and Kymera Advance SAR447971 Into First-in-Human Trial, Setting Up New Optionality in Inflammatory Skin Disease
1M ago
SNY
KYMR
Kymera Therapeutics initiated with a Buy at Canaccord
PremiumThe FlyKymera Therapeutics initiated with a Buy at Canaccord
2M ago
KYMR
Kymera Therapeutics initiated with a Buy at Canaccord
Premium
The Fly
Kymera Therapeutics initiated with a Buy at Canaccord
2M ago
KYMR
AMD upgraded, Reddit downgraded: Wall Street’s top analyst calls
Premium
The Fly
AMD upgraded, Reddit downgraded: Wall Street’s top analyst calls
2M ago
BX
FG

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >